Wound Care News

By Industry News

January 16, 2020 – Smith+Nephew, the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced wound area, depth and volume compared to traditional negative pressure wound therapy (tNPWT) in patients with lower extremity ulcers.

By Industry News

Boston, Massachusetts (Jan. 15, 2020) ⁠— Healthy.io, the category creator of smartphone urinalysis and a leader in turning smartphone cameras into clinical-grade medical devices, announced the launch of its second product line, a digital wound management solution. The solution is an extension of Healthy.io’s clinical grade color recognition products in use by tens of thousands of people worldwide and helps healthcare professionals objectively assess chronic wounds and track their progress over time through a repeatable process. The solution was successfully registered with the U.S. Food and Drug Administration (FDA) in December 2019.

By Industry News

Atlantic Beach, FL – December 20, 2019 – Registration for the first virtual wound care conference, WoundCon, begins today. WoundCon will be held on April 2nd, 2020 and is hosted by Kestrel Health Information, Inc., the publisher of WoundSource, the leading wound care product reference guide for health care professionals. WoundCon will be free for all health care professionals and will offer multiple opportunities to earn CE/CME credits. The theme for the conference is “Learn today, apply tomorrow.”

By Industry News

Toronto, Canada – December 5, 2019 – MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of fluorescence in wounds, has received FDA 510(k) clearance for its i:X® handheld fluorescence imaging device for use in the detection of wounds containing bacteria. This FDA 510(k) clearance is an expansion of the original de novo clearance for the MolecuLight i:X platform, granted on August 14, 2018. The MolecuLight i:X enables real time point-of-care visualization of fluorescence in wounds and measures wounds and digitally records all images and area measurements. The i:X’s fluorescence image, when used in combination with clinical signs and symptoms (CSS), has been shown to increase the likelihood that clinicians can identify wounds containing bacterial loads of >104 CFU/g (colony-forming units per gram) as compared to examination of CSS alone. In addition to the 510(k), the MolecuLight i:X also has CE marking allowing for its sale in Europe and is approved by Health Canada for sale in Canada.

Edison, NJ (November 18, 2019) – MTF Biologics, a global nonprofit organization dedicated to saving and healing lives through organ and tissue donation, is introducing Leneva™ – Allograft Adipose Matrix and SomaGen™ Meshed – Allograft Dermal Matrix to its line of premier, innovative and effective wound care solutions. Developed to advance the treatment of complex surgical wounds, these first-to-market tissue forms aid in tissue reconstruction and wound closure by providing protective coverage and promoting tissue integration.

By Industry News

Atlantic Beach, FL – November 15, 2019 – Kestrel Health Information, Inc., the publisher of WoundSource®, is excited to announce it will be hosting their first online virtual wound care conference, WoundCon, on April 2, 2020. The conference will be free for attendees, who will have the opportunity to earn CE/CME credits.

By the WoundSource Editors

Toronto, Canada – November 4, 2019 – MolecuLight Inc., the world's leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, has been informed by the American Medical Association (AMA) that in its summary of panel actions September 2019 meeting, the CPT® Editorial Panel accepted the addition of new Category III codes 0X30T, 0X31T to report "wound bacterial localization and treatment" effective date July 1, 2020 to enable a reimbursement pathway for point-of-care fluorescence wound imaging. At that time a novel code excluding the "X" will be reported by the AMA when the final datafiles are distributed by the AMA. Point-of-care fluorescence wound imaging is achieved using MolecuLight's handheld fluorescence imaging device, the i:X®.

By Industry News

Salt Lake City, UT– October 31, 2019 – PolarityTE, Inc., a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced findings from an open-label, single-arm pilot study, which examined the impact of SkinTE™, a novel human cellular and tissue-based product derived from a patient's own skin, in closing venous stasis leg ulcers (VLUs) following failure of conventional treatments. The clinical outcomes were reported in a poster presentation, entitled Pilot Study Assessing Novel Autologous Homologous Skin Construct Treatment of Venous Stasis Leg Ulcers, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, held in Las Vegas, October 12-14, 2019. In addition, the study poster abstract received the highest scores from reviewers in the Case Series/Study Category, the largest category at the conference.

March 2, 1939 – September 15, 2019

Dr. Edward Stout, PhD, was the founder of Southwest Technologies and the inventor of both Elasto-Gel™ and the first microwavable/dual hot/cold pack. Dr. Stout created Southwest Technologies in 1981 with the vision of "treating the world well," a statement that followed him throughout life. In 1987, he received FDA permission to expand Elasto-Gel™ technology into applications for wound and scar management and for padding materials. He continued to develop health care products while always keeping patients' needs in mind. Those who knew him say he was always happy to tell stories about Southwest Technologies and how it got its start.

By Industry News

Houston, TX – October 29, 2019 – Vapogenix, a clinical-stage company developing a new class of topical non-opioid, lidocaine-free analgesics, today announced results of a Phase II clinical trial of its lead product, VPX638, which demonstrate rapid onset and sustained duration of pain relief and reduced opioid use for patients with painful wounds.